Abstract
Dasatinib is efficient in vitro against most of CML cells harboring ABL kinase domain mutations and induces high rates of response in imatinib-resistant CML patients. Here, we monitored the mutated BCR-ABL transcripts during the follow-up of 12 CML patients treated with dasatinib. We identified four groups of patients based on their sensitivity to dasatinib. Clinical responses were correlated to the in vitro sensitivity of BCR-ABL mutants to dasatinib, however, some discrepancies were observed in a subfraction of CML patients, suggesting subtle differences between in vitro observations and clinical entities and/or the onset of other mechanisms responsible for dasatinib resistance.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Benzamides
-
Dasatinib
-
Drug Resistance, Neoplasm / drug effects
-
Drug Resistance, Neoplasm / genetics*
-
Female
-
Follow-Up Studies
-
Fusion Proteins, bcr-abl / genetics*
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Male
-
Middle Aged
-
Mutation*
-
Piperazines / administration & dosage
-
Polymorphism, Restriction Fragment Length*
-
Protein Kinase Inhibitors / administration & dosage*
-
Pyrimidines / administration & dosage*
-
Thiazoles / administration & dosage*
Substances
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Thiazoles
-
Imatinib Mesylate
-
Fusion Proteins, bcr-abl
-
Dasatinib